ArticleNPJ vaccines2025
Cocktail vaccine induces immunoprotection and modulates the fecal microbiota in dogs against Echinococcus granulosus infection.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oral administration of recombinant Bacillus subtilis spores induces protective immunity against Echinococcus granulosus infection in dogs.Parasites & vectors · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cystic echinococcosis (CE) is a global zoonotic parasitic disease that represents a significant public health challenge. Although vaccination is considered an ideal strategy for controlling CE, no effective vaccines are currently available for dogs. Herein, bioinformatic approaches were employed to identify vaccine candidates. The selected proteins, including Echinococcus granulosus enolase (EgENO), severin (EgSev), cyclophilin (EgCyc), fatty acid-binding protein 1 (EgFABP1), calmodulin (EgCaM), and serine protease inhibitor 1 (EgSrp1), were expressed in Escherichia coli. These proteins were grouped into cocktail vaccines: rEgENO&rEgSev&rEgCyc and rEgFABP1&rEgCaM&rEgSrp1, and were combined with the Quil-A adjuvant to evaluate vaccine efficacy in beagles. After two subcutaneous immunizations, the rEgENO&rEgSev&rEgCyc and rEgFABP1&rEgCaM&rEgSrp1 vaccines reduced the parasite burden by 80.58% (p < 0.01) and 47.92% (p < 0.01), respectively. Additionally, Ligilactobacillus, Fusobacterium, and Streptococcus correlated significantly with immunoprotection. This study demonstrated bioinformatically screened antigens were effective vaccine candidates, and vaccine-microbiota interactions provided a potential strategy to improve vaccine efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.